Aripirazole-Long Acting Injectable in Pregnant Women with Schizophrenia: A Case Series
Introduction Long-acting injectable antipsychotics (LAIs) have emerged as a new therapeutic option to treat patients suffering a psychotic disorder. To date, there is a lack of studies regarding safety and clinical use pattern of LAIs in pregnant women. Objectives Provide evidence and real world cli...
Saved in:
Published in | European psychiatry Vol. 65; no. S1; pp. S129 - S130 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Paris
Cambridge University Press
01.06.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Introduction
Long-acting injectable antipsychotics (LAIs) have emerged as a new therapeutic option to treat patients suffering a psychotic disorder. To date, there is a lack of studies regarding safety and clinical use pattern of LAIs in pregnant women.
Objectives
Provide evidence and real world clinical data of pregnant women with schizophrenia who have been treated with long-acting aripiprazole monohydrate (aripiprazole once monthly [AOM] condition) during their pregnancy.
Methods
Descriptive real-world clinical experiences of pregnant women in treatment with AOM. The information was obtained by reviewing electronic medical records and by direct clinical observation management.
Results
The first six case-series describing the pregnancy course of women with schizophrenia treated with AOM. All of them remained psychopathologically stable through pregnancy, and their infants became healthy with normal developmental milestones (Table 1).
Table 1.
Clinical characteristics of six case-reports.
Mothers
1
2
3
4
5
6
Maternal/Pregnancy outcomes
Age(years)
35
29
35
31
38
30
Diagnosis
Schizophrenia
Schizophrenia
Schizophrenia
Schizophrenia
Schizophrenia
Schizophrenia
AOM(mg/days)
400-300
400-300
400-300
160
300
400
Type of delivery
Eutocic.
Eutocic, preterm
Eutocic
Eutocic
Eutocic
Eutocic
Neonatal outcomes
Weight(grams)
3300
1800
3140
3102
2940
3400
Gender
Female
Female
Male
Male
Male
Male
Developmental
Abnormalities
(years)
No(3)
No(2)
No( 0.17)
No(2)
No(2)
No(1.5)
Conclusions
The favorable results in this case-series suggest that despite the lack of evidence on reproductive safety and treatment with AOM during pregnancy, this therapeutic option should be considered in pregnant women with schizophrenia. However, further research on the use of long-acting antipsychotics in pregnant women is needed.
Disclosure
No significant relationships. |
---|---|
ISSN: | 0924-9338 1778-3585 |
DOI: | 10.1192/j.eurpsy.2022.355 |